These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19885841)

  • 1. FEZ1/LZTS1 protein expression in ovarian cancer.
    Califano D; Pignata S; Pisano C; Greggi S; Laurelli G; Losito NS; Ottaiano A; Gallipoli A; Pasquinelli R; De Simone V; Cirombella R; Fusco A; Chiappetta G
    J Cell Physiol; 2010 Feb; 222(2):382-6. PubMed ID: 19885841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
    Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
    J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.
    Nonaka D; Fabbri A; Roz L; Mariani L; Vecchione A; Moore GW; Tavecchio L; Croce CM; Sozzi G
    Cancer Res; 2005 Feb; 65(4):1207-12. PubMed ID: 15735004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fez1/lzts1 alterations in gastric carcinoma.
    Vecchione A; Ishii H; Shiao YH; Trapasso F; Rugge M; Tamburrino JF; Murakumo Y; Alder H; Croce CM; Baffa R
    Clin Cancer Res; 2001 Jun; 7(6):1546-52. PubMed ID: 11410489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
    Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B
    Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.
    Vecchione A; Galetti TP; Gardiman M; Ishii H; Giarnieri E; Pagano F; Gomella LG; Croce CM; Baffa R
    BMC Urol; 2004 Sep; 4():11. PubMed ID: 15357873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
    Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
    Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
    Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
    Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
    Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
    Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.
    Ishii H; Vecchione A; Murakumo Y; Baldassarre G; Numata S; Trapasso F; Alder H; Baffa R; Croce CM
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10374-9. PubMed ID: 11504921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and expression analysis of LZTS1 in ovarian cancer.
    Arnold JM; Choong DY; Lai J; Campbell IG; Chenevix-Trench G
    Cancer Lett; 2006 Feb; 233(1):151-7. PubMed ID: 15876481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.
    Yi X; Zhou Y; Zheng W; Chambers SK
    Aust N Z J Obstet Gynaecol; 2009 Feb; 49(1):93-8. PubMed ID: 19281587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.
    Vecchione A; Ishii H; Baldassarre G; Bassi P; Trapasso F; Alder H; Pagano F; Gomella LG; Croce CM; Baffa R
    Am J Pathol; 2002 Apr; 160(4):1345-52. PubMed ID: 11943719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
    Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
    Jewell EL; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis.
    Baffa R; Fassan M; Sevignani C; Vecchione A; Ishii H; Giarnieri E; Iozzo RV; Gomella LG; Croce CM
    Carcinogenesis; 2008 Apr; 29(4):846-8. PubMed ID: 18192690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
    Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
    Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.